NYSE:BAX

Baxter Stock Plummets 15% After Mixed Q3 Earnings – What Investors Should Know

Baxter shares fell about 16% to $19 on Oct. 30 after cutting its 2025 outlook and missing Q3 sales forecasts. Q3 revenue rose 5% to $2.84 billion, but sales missed estimates; adjusted EPS of $0.69 beat expectations. The company halted Novum IQ infusion pump shipments after two patient deaths and reported hurricane-related supply disruptions. Andrew Hider became CEO in July.

30 October 2025

Earnings Reports·NYSE:BAX

Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

China researchers reported a hydrogel “smart” wound dressing that closed 90% of diabetic ulcers in mice within 12 days by delivering microRNA vesicles. The FDA approved Boehringer Ingelheim’s Hernexeos for advanced non-squamous NSCLC, with 75% of treated patients seeing tumors shrink or disappear. U.S. IV saline shortages ended as Baxter’s North Carolina plant resumed production after hurricane damage.

10 August 2025

NASDAQ:BLUE·NASDAQ:BNTX·NASDAQ:CVAC·NYSE:BAX·NYSE:PFE·Pharmaceuticals·XETRA:BAYN

Nasdaq, S&P, Dow Futures Gain as Netanyahu Calms Iran Conflict Fears
March 20, 2026, 4:43 AM EDT. U.S. stock index futures climbed sharply on Friday following remarks by Israeli Prime Minister Benjamin Netanyahu. He announced that Israel is assisting in reopening the Strait of Hormuz, easing tensions over the Iran conflict. The S&P 500 futures rose 0.90%, while Nasdaq 100 and Dow futures also advanced, reflecting renewed investor confidence. The Strait of Hormuz is a strategic oil transit choke point; its reopening reduces fears of supply disruptions. Market sentiment showed clear improvement amid geopolitical worries, with investors favoring risk assets ahead of the weekend. This development was seen as a potential de-escalation in one of the region's most volatile flashpoints.